A complete list of peer reviewed original research papers, book chapters and invited reviews.

• C.J. Holmes (2016).   Abnormalities of host defense mechanisms during peritoneal dialysis.  Chapter 34 in “Dialysis Therapy” eds Nissenson, AR and Fine, R N.  4th edition. Elsevier, Amsterdam.

• J.K Leypoldt, C.M. Hoff, D. Piscopo, S.N. Carr, J.M. Svatek, A. Akonaur and C.J. Holmes (2015).  Low polydispersity glucose polymers as osmotic agents for peritoneal dialysis. Peritoneal Dialysis International 35:428-435.

• A. Akonaur, C.J. Holmes and J.K. Leypoldt (2015).  Predicting the peritoneal absorption of icodextrin in rats and humans including the effect of a-amylase activity in dialysate.  Peritoneal Dialysis International 35:288-296.

• A. Akonaur, C.J. Holmes and J.K. Leypoldt (2014).  Peritoneal residual volumes induce variability of ultrafiltration with icodextrin.  Peritoneal Dialysis International 34:95-99.

• J.K. Leypoldt, C.J. Holmes and P. Rutherford (2012).  Clearance of middle molecules during haemodialysis and haemofiltration: new insights – editorial.  Nephrology, Dialysis and Transplantation 27:4245-4247.

• J.K Leypoldt, D. Piscopo, S.N. Carr, J.M. Svatek, C.J. Holmes and C.M. Hoff (2012).  Ultrafiltration characteristics of glucose polymers with low polydispersity.  Peritoneal Dialysis International 33:124-131.

• B.L. Riser, F.C. Barreto, R. Rezg, P.W. Valaitis, C.S. Cook, J.A. White, J.H. Glass, J. Maizel, L. Louver, T.B. Drueke, C.J. Holmes and Z.A. Massy (2011).  Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model or uremia.  Nephrology, Dialysis and Transplantation 0:1-9.

• C.J. Holmes (2009).  Ultrafiltration and the buffer: one more interaction to consider?  Peritoneal Dialysis International 29:20-22.

• C.J. Holmes (2009).  Reducing Cardio-metabolic risk in peritoneal dialysis patients: role of the dialysis solution.  Journal of Diabetes Science and Technology 3(6):1472-1480.

• K. Pawlaczyk, C.J. Holmes, S. Czekalski, A. Breborowicz and B. Lindholm (2009).  Effects of bicarbonate/lactate dialysis solution on the inflammatory response of spontaneous peritonitis in rats undergoing chronic peritoneal dialysis.  Blood Purification 28:200-208.

• A. Akonur, C.J. Holmes and J.K. Leypoldt (2008).  Ultrafiltration efficiency during automated peritoneal dialysis (APD) using glucose-based solutions.  Advances in Peritoneal Dialysis 24:69-74.

• C.J. Holmes (2007).  Glucotoxicity in peritoneal dialysis – solutions to the solution!  American Journal of Chronic Kidney Disease 14(3):269-278.

• C.J. Holmes (2007).   Abnormalities of host defense mechanisms during peritoneal dialysis.  In “Dialysis Therapy” eds Nissenson, AR and Fine, R N.  3rd edition. Hanley and Belfus, Inc. Philadelphia, pp. 235-238.

• S. Mujais and C.J. Holmes (2006).  Modern Peritoneal Dialysis: Concepts and Approaches (Editorial).  Kidney International 70; suppl 103:s1-s2.

• C.J. Holmes and S. Mujais (2006).  Glucose sparing in peritoneal dialysis: Implications and metrics.  Kidney International 70; suppl 103:s104-s109.

• Y. Maruyama, L. Nordfors, P. Stenvinckel, O. Heimburger, P. Barany, R. Pecoits-Filho, J. Axelsson, C.M. Hoff, C.J. Holmes and B. Lindholm (2005).  Interleukin-1 gene cluster polymorphisms are associated with nutritional status and inflammation in patients with end stage renal disease.  Blood Purification 23:384-393.

• B. Piraino, G.R. Bailie, J. Bernardini, E. Boeschoten, A. Gupta, C.J. Holmes, E.J. Kuijper, P. Kam-Tao Li, W.C. Lye, S. Mujais, D. Paterson, M. Perez Fontan, A. Ramos, F. Schaefer and L. Uttley (2005).  Peritoneal Dialysis Related Infections Recommendations.  Peritoneal Dialysis International 25(2):107-131.

• P. Stenvinckel, K. Wang, A.B. Qureshi, J. Axelsson, R. Pecoits-Filho, P. Giao, P. Barany, B. Lindholm, T. Jogestrand, O. Heimburger, C.J. Holmes, M. Schalling, and L. Nordfors (2005).  Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney International 67:1-10.

• P. Margetts, P. Bonniard, L.M. Liu, C.M. Hoff and C.J. Holmes, J.A. West-Mays and M.M. Kelly (2005).  Transient overexpression of transforming growth factor b1 induces epithelial mesenchymal transition in the rodent peritoneum.  Journal of the American Society of Nephrology 16:425-436.

• T. Shockley and C.J. Holmes (2004).  Zukünftige Technologien für die Nierenersatztheraoie (Future Technologies for Renal Replacement Therapies.  In “Dialyseverfahren in Klinik und Praxis”.  Editors: W.H. Hörl and C. Wanner.  Georg Thieme Verlag, Stuttgart, pp. 649-656.

• M. Numata, M. Nakayama, T. Hosoya, C.M. Hoff, C.J. Holmes, M. Schalling, L. Nordfors and B. Lindholm (2004).  Possible pathological involvement of receptor for advanced glycation end products (RAGE) for development of encapsulating peritoneal sclerosis in Japanese CAPD patients.  Clinical Nephrology 62(6):455-460.

• C. J. Holmes, A. Degremont, W. Kubey, P. Straka, N.K. Man Y (2004).  Effectiveness of various chemical disinfectants versus cleaning combined with heat disinfection on Pseudomonas biofilm in hemodialysis machines.   Blood Purification 22:461-468.

• P. Stenvinckel, A. Marchlewska, R. Pecoits-Filho, O. Heimburger, Z. Zhang, C. Hoff, C.J. Holmes, J. Axelsson, S. Andersson, M. Schalling, P. Barany, B. Lindholm and L. Nordfors (2004).  Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin.  Kidney International 65:274-281.

• R. Pecoits-Filho, P. Stenvinckel, A. Marchlewska, O. Heimburger, P. Barany, C.M. Hoff, C.J. Holmes, B. Lindholm, M. Schalling and L. Nordfors (2003).  A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end stage renal disease.  Kidney International 63 (suppl 84):S172-S176.

• O. Heimburger, S. Mujais and C.J. Holmes (2003).  Editor’s Introduction: Optimizing acid-base balance and membrane viability in peritoneal dialysis.  Kidney International 64 (suppl 88):S1-S2.

• R. Mackenzie, C.J. Holmes, S. Jones, J.D. Williams and N. Topley (2003).  Ex vivo studies in peritoneal dialysis patients.  Kidney International 64 (suppl 88):S84-S93.

• C.J. Holmes and D. Faict (2003).   Peritoneal dialysis solution biocompatibility – definitions and evaluation strategies.  Kidney International 64 (suppl 88):S50-S56

• L. Skoufos, N. Topley, L. Cooker, A. Dawnay, D.J. Millar, C.J. Holmes and D. Faict (2003).  The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate buffered peritoneal dialysis fluid.  Kidney International 64 (suppl 88):S94-S99.

• A. Puig-Kroger, O. Munoz-Pello, R. Selgas, G. Criado, M-A. Bajo, J.A. Sanchez-Tomero, V. Alvarez, G. del Peso, P. Sanchez-Mateos, C.J. Holmes, D. Faict, M. Lopez-Cabrera, J. Madrenas and A. Corbi (2003).  Peritoneal dialysis solutions inhibit the differentiation and maturation of human monocyte-derived dendritic cells: effect of lactate and glucose-degradation products.  Journal of Leukocyte Biology 73:482-492.

• P.J. Margetts, M. Kolb, L. Yu, C.M. Hoff, C.J. Holmes, D.C. Anthony, F. Pitosso and J. Gauldie (2002).  Inflammatory cytokines and the effect on structure and function of the rat peritoneum.  American Journal of Pathology 160(6):2285-2294.

• C.J. Holmes (2002).   Abnormalities of host defense mechanisms during peritoneal dialysis.  In “Dialysis Therapy” eds Nissenson, AR and Fine, R N.  3rd edition. Hanley and Belfus, Inc. Philadelphia, pp. 235-238.

• P.J. Margetts, S. Gyorffy, M. Kolb, L. Yu, C.M. Hoff, C.J. Holmes and J. Gauldie (2002).  Anti-angiogenic and anti-fibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats.  Journal of the American Society of Nephrology 13:721-728.

• L. Cooker, C.J. Holmes and C.M. Hoff (2002).  Invited Review: The biocompatibility of icodextrin.  Kidney International 62 (suppl 81):S34-S35.

• S. Jones, C.J. Holmes , R. Mackenzie, R. Stead, G.A. Coles, J.D. Williams, D. Faict, and N. Topley (2002).  Continuous Dialysis with Bicarbonate/lactate peritoneal dialysis fluids results in a long term improvement of ex vivo peritoneal macrophage function.  Journal of the American Society of Nephrology 13:S97-S103.

• D.J. Millar, G.W. Taylor, P.J. Thornalley, C.J. Holmes and A. Dawnay (2002).  Comparison of in vitro protein modification with advanced glycation endproduct (AGE) precursors methylglyoxal, glyoxal, 3-deoxyglucosone and glucose using mass spectrometry.  International Congress Series 1245:353-354.

• D.J. Millar, P.J. Thornalley, C.J. Holmes and A. Dawnay (2002).  In vitro kinetics of AGE formation resembles that of glucose degradation products rather than glucose.  International Congress Series 1245:475-477.

• L.C. Cooker, P. Luneburg, C.J. Holmes and N. Topley (2001).  Interleukin 6 levels in effluent from patients dialyzed with bicarbonate/lactate based peritoneal dialysis solutions.  Peritoneal Dialysis International 21(suppl 3):S102-S107.

• C.J. Holmes (2001).  Biocompatibility of new PD solutions: relevance of pre-clinical studies.  Peritoneal Dialysis International 20(suppl 5):S5-S9.

• S. Jones, C. J. Holmes, R. T. Krediet, D. Faict, A. Tranaeus, J. D. Williams, G. A. Coles, and N. Topley, on behalf of the Bicarbonate/Lactate Study Group(2001).  Continuous dialysis with bicarbonate/lactate based peritoneal dialysis solution is associated with an increase in dialysate CA125 and a decrease in hyaluronic acid levels.  Kidney International 59(4):1529-1538.

• M.S. Park, J.K. Kim, C.J. Holmes, M.F. Weiss (2001).  Effects of bicarbonate/lactate solution on peritoneal AGE accumulation.  Peritoneal Dialysis International 20(suppl 5):S33-S38.

• W. Kubey, P. Straka and C.J. Holmes (2001).  An in vitro bacterial touch contamination risk assessment of two CAPD twinbag systems.  Blood Purification 19:62-67.

• W.F. Keane, G.R. Bailie, E. Boeschoten, R. Gokal, T.A. Golper, C.J. Holmes, Y. Kawaguchi, B. Piraino, M. Riella and S. Vas (2000).  Adult peritoneal dialysis related-peritonitis treatment recommendations.  2000 Update.  The Ad Hoc Committee on Peritonitis Management for the International Society for Peritoneal Dialysis. Peritoneal Dialysis International 20(4):396-411.

• L. Martis, N. Topley and C.J. Holmes (2000).  Conventional and newer peritoneal dialysis solutions.  In ‘Dialysis and Transplantation: A companion to Brenner and Rector’s ‘The Kidney’.  Editors M.H. Sayegh, W. Owen and B. Pereira. W.B. Saunders Company, pp. 179-197. 

• C.J. Holmes and Ty Shockley (2000).  Strategies to reduce glucose exposure in peritoneal dialysis patients.  Peritoneal Dialysis International 20(Suppl 2):S37-S41.

• R.K. Mackenzie, S. Jones, A. Moseley, C.J. Holmes, R. Argyle, J.D. Williams, G.A. Coles, D. Faict and N. Topley (2000).  In vivo exposure to bicarbonate/lactate buffered peritoneal dialysis fluids improves ex vivo macrophage function.  American Journal of Kidney Diseases 35(1):112-121.

• K. Pawlaczyk, M. Kuzlan-Pawlaczyk, K. Wieczorowska-Tobis, A. Polubinska, J. Wioeniewska, D. Faict, C.J. Holmes, A. Breborowicz (1999).  Bicarbonate-lactate dialysis solution improves in vivo function of peritoneal host defense in rats.  Peritoneal Dialysis International.  Peritoneal Dialysis International 19(2):S370-S377.

• C.J. Holmes (1999).  Choice of biocompatibility criteria for peritoneal dialysis solutions.  In ‘Quality Assurance in Dialysis’.  Editors: L. Henderson and R. Thuma.  Kluwer Academic Publishers, Dordrecht, The Netherlands, pp. 257-265.

• J. LaIuppa and C.J. Holmes (1999).  Percutaneous access for peritoneal dialysis: a tissue engineering approach.  In ‘The Artificial Kidney: Physiological modeling and tissue engineering’.  Ed. John K. Leypoldt. R.G. Landes Company, pp. 101-124.

• L.A. Cooker, C.G. Choo, P. Luneburg, J. Lamella, C.J. Holmes (1999). Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro.  Advances in Peritoneal Dialysis 15:17-20.

• R.K. Mackenzie, C.J. Holmes, A. Moseley, J. Jenkins, J.D. Williams, G.A. Coles, D. Faict and N. Topley (1998). Bicarbonate/lactate and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFa secretion.  Journal of the American Society of Nephrology 9:1499-1506.

• Kubey, P. Straka and C.J. Holmes (1998). The importance of product design on effective bacterial removal by fluid convection in Y set and Twin Bag systems.  Blood Purification 16:154-161.

• R. Gokal, S. Alexander, S. Ash, T.W. Chen, A. Danielson, C.J. Holmes, P. Joffe, J. Moncrief, K. Nichols, B. Piraino, B. Prowant, A. Slingeneyer, B. Stegmayr, Z. Twardowski and S. Vas (1998).  Peritoneal catheters and exit site practices toward optimum peritoneal access: 1998 update.  Peritoneal Dialysis International 18:11-33.

• D.J. Millar, C.J. Holmes, D. Faict and A. Dawnay (1998).  Comparison of in vitro AGE formation between standard PD fluid and a novel bicarbonate/lactate formulation. Advances in Peritoneal Dialysis 14:191-194.

• B. Rogachev, M.J. Hausmann, R. Yulzari, M. Weiler, C.J. Holmes, D. Faict, C. Chaimovitz and A. Douvdevani (1997).  The effect of bicarbonate-based dialysis solutions (PDS) on pHi and TNFa production by peritoneal macrophages.  Peritoneal Dialysis International 17(6): 546-553.

• S. Sundaram, M. Cendoroglo, L.A. Cooker, B.J. Jaber, D. Faict, C.J. Holmes and B.J.G. Pereira (1997).  Effect of two-chambered bicarbonate-lactate buffered peritoneal dialysis fluids on peripheral blood mononuclear cell (PBMC) and polymorphonuclear (PMN) cell function in vitro.  American Journal of Kidney Disease 30(5): 680-689.

• C.J. Holmes and N. Topley (1997).  Adhesion molecules in defense of the peritoneum.  In ‘Adhesion Molecules in Health and Disease.’  Editors: L.C. Paul and T.B. Issekutz; Marcel Dekker, Inc., pp. 709-734.

• L.A. Cooker, P. Luneburg, D. Faict, C. Choo and C.J. Holmes (1997).  Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions in two chambered bags.  Peritoneal Dialysis International 17(4):373-378.

• S.L. Lewis, S.G. Kutvirt, L.C. Seamer and C.J. Holmes (1997).  Calcium metabolism in blood and peritoneal lymphocytes from continuous ambulatory peritoneal dialysis patients.  Peritoneal Dialysis International 17(3):287-294.

• S.L. Lewis and C.J. Holmes (1996).  Editor’s Introduction: Infectious problems in dialysis patients (Part I).  Advances in Renal Replacement Therapy 3(3):200.

• S.L. Lewis and C.J. Holmes (1996).  Editor’s Introduction: Infectious problems in dialysis patients (Part II).  Advances in Renal Replacement Therapy 3(4):274.

• W.F. Keane, S.R. Alexander, G.R. Bailie, E. Boeschoten, R. Gokal, T.A. Golper, C.J. Holmes, C.C. Huang, Y. Kawaguchi, B. Piraino, M. Riella and S. Vas (1996).  Peritoneal dialysis related peritonitis treatment recommendations.  1996 Update.  The Advisory Committee on Peritonitis Management for the International Society for Peritoneal Dialysis. Peritoneal Dialysis International 16(6):557-573.

• The Mupirocin Study Group {including C.J. Holmes} (1996). Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis.  Journal of the American Society of Nephrology 7(11):2403-2408.

• N. Topley, D. Kaur, M.M. Petersen, A. Jörres, J.D. Williams, D. Faict and C.J. Holmes (1996).  In vitro biocompatibility comparison of bicarbonate versus bicarbonate-lactate buffered peritoneal dialysis solution on human mesothelial cell and neutrophils.  Journal of the American Society of Nephrology 7(2):218-224.

• R.D. Swartz and C.J. Holmes (1996).  ‘Macrophages’, in ‘Images in Clinical Medicine’.  New England Journal of Medicine 333(23):1546.

• C.J. Holmes (1996).  Peritoneal Host Defense mechanisms (short communication).  Peritoneal Dialysis International 16(Suppl 1):S123-S125.

• C.J. Holmes (1995).  Invited Review: Hemodialyzer Performance: Biological Indices.  Artificial Organs 19(11):1126-1135.

• C.J. Holmes, Kubey W, Luneburg P, Ericson S, Brown J (1995).  A longitudinal in vitro antimicrobial evaluation of two silver polymer surface treatments for peritoneal dialysis catheters.  Advances in Peritoneal Dialysis Vol. 11, p.193-196.

• P. Straka, W. Kubey, P. Luneburg, K. Pu, C.J. Holmes (1995).  The ‘Flush’ procedure of Twinbag systems (short communication).  Peritoneal Dialysis International 15(8):390-391.

• C.J. Holmes and R.C. Evans (1995).  In vitro studies of cytokine-inducing substance (CIS) transfer across hemodialysis membranes – a cautionary note.  Nephrology Dialysis Transplantation 10(1):139.

• C.J. Holmes (1994).  Invited Review: Peritoneal immunity in peritoneal dialysis patients.  Kidney International 46 (Suppl. 48):S58-S70.

• C.J. Holmes, R.C. Evans and L.W. Henderson (1994).  The role of plasma in the transfer of cytokine-inducing substances across cellulosic membranes.  Journal of Laboratory and Clinical Medicine 124:782-788.  Associated journal editorial by Dr. R. Hakim: Endotoxin transfer during dialysis – less than meets the eye?

• C. J. Holmes (1994).  Enhancing host defenses in peritoneal dialysis.  An invited opinion in the ‘Dialysis Clinic’ section.  Seminars in Dialysis 7(1):75-76.

• R. Gokal, S.R. Ash, G. Baird-Helfrich, C.J. Holmes, P. Joffe, W.K. Nichols, D. Oreopoulos, J. Reitinger, M.C. Riella, A. Slingeneyer, Z.J. Twardowski and S.I. Vas (1993).  Peritoneal catheters and exit site practices – toward optimal peritoneal access.  Peritoneal Dialysis International 13(1):29-39.
• C.J. Holmes (1993).  Biocompatibility of peritoneal dialysis solutions {Editorial review}.  Peritoneal Dialysis International 13(2):88-94.

• C.J. Holmes (1993).  Dialyzer reprocessing using heat: scientific and technical considerations.  Blood Purification 11: 384-391.

• C.J. Holmes (1993).   Abnormalities of host defense mechanisms during peritoneal dialysis.  In “Dialysis Therapy” Editors: Nissenson, AR and Fine, R N.  2nd edition. Hanley and Belfus, Inc. Philadelphia, pp 161-165.

• S. L. Lewis, S.A. Young, B.J. Wood, K.S. Morgan, D.G. Erickson and C.J. Holmes (1993).  Relationship between persistent peritonitis and altered immune status.  American Journal Kidney Disease 22(3): 456-461.

• S.L. Lewis and C.J. Holmes (1993).  Host defense mechanisms involved in peritonitis.   Peritoneal Dialysis International 13(2):S295-S298.

• C.J. Holmes (1993). Peritoneal immune defense: clinical relevance and practical implications.  Proceedings of VIth Congress of the International Society for Peritoneal Dialysis in Peritoneal Dialysis International 13(2):S278-S281.

• L. Martis, T. Shockley and C.J. Holmes (1993).  Experimental peritoneal dialysis solutions.  Peritoneal Dialysis International 13(2):S98-S100.

• S.L. Lewis, S.G. Kutvirt, C.L. Cooper, P.N. Bonner and C.J. Holmes (1993).  Characteristics of peripheral and peritoneal lymphocytes from continuous ambulatory peritoneal dialysis patients.  Peritoneal Dialysis International 13(2):S273-S277.

• S.L. Lewis, C.L. Cooper, P.N. Bonner and C.J. Holmes (1992).  Prospective analysis of blood and peritoneal lymphocytes from continuous ambulatory peritoneal dialysis patients. Journal of Laboratory and Clinical Immunology 37: 3-19.

• W. Kubey and C.J. Holmes (1992).  The relationship between peritoneal dialysate absorbance of ultraviolet light and the microbiocidal effectiveness of mercury vapor and xenon flash UV disinfection systems for CAPD.  Current concepts in peritoneal dialysis, eds. Ota K, Maher J, Winchester J and Hirszel P, Exerpta Medica, pp 223-227.

• C.J. Holmes, W. Kubey and P. Luneburg (1992).  Disinfection of CAPD solution bag medication ports.  Peritoneal Dialysis International, 12:326-327.

• R. Swartz, J. Messana,  C.J. Holmes and J. Williams (1991).  Biofilm formation on peritoneal catheters does not require the presence of infection.  ASAIO Transactions XXXVII: 626-634.

• S.L. Lewis and C.J. Holmes (1991).  Invited Review: Host defense mechanisms of the peritoneal cavity of chronic peritoneal dialysis patients I. Cellular defenses.  Peritoneal Dialysis International 11(1):14-21.

• C.J. Holmes and S.L. Lewis (1991).  Invited Review: Host defense mechanisms of the peritoneal cavity of chronic peritoneal dialysis patients II. Humoral defenses.  Peritoneal Dialysis International 11(3):112-117.

• W. Kubey and C.J. Holmes (1991).  An in vitro evaluation of the microbiocidal effectiveness of a Xenon-sourced ultraviolet light system for CAPD connections.  Blood Purification 9:102-108. 

• R. C. Evans and C.J. Holmes (1991).  In vitro studies on the transfer of cytokine-inducing substances across selected high flux hemodialysis membranes.  Blood Purification 9:92-101.

• M. Sekkarie, C.J. Holmes, U. Ranjit and C. Kauffman (1991).  Grossly visible fungal colonization of a Tenckhoff catheter: a case report and literature review.  Peritoneal Dialysis International 11(1):85-87.

• C.J. Holmes (1990).  CAPD associated peritonitis: an immunological perspective on causes and interventions.  In ‘Immunologic Perspectives in Chronic Renal Failure’.  Gurland HJ, Moran J, Wetsels E (eds).  Contributions to Nephrology, Basel, Karger, vol 86, pp 73-90.

• C.J. Holmes (1990).  Catheter-associated biofilm. In ‘CAPD: Host Defence, Nutrition and Ultrafiltration’.  Coles GA, Davies M, Williams JD (eds).  Contributions to Nephrology, Basel, Karger, vol 85, pp 49-56.

• S.L. Lewis, P.J. Norris and C.J. Holmes (1990).  Phenotypic characterization of monocytes/macrophages from CAPD patients.  ASAIO Transactions 36:M575-M577.

• C.J. Holmes and R.C. Evans (1989).  Resistance of bacterial biofilms to antibiotics.  Journal of Antimicrobial Chemotherapy 24(1):85. 

• C.J. Holmes, S.L. Lewis, W. Kubey and D.E. Van Epps (1989).  Comparison of peritoneal WBC parameters from CAPD patients identified as high or low peritonitis incidence individuals.  American Journal of Kidney Diseases Vol XV 3:258-264.

• D.L. Sewell, T.A. Golper, P.B. Hulman, C.M. Thomas, L.M. West, W.Y. Kubey and C.J. Holmes (1989).  Comparison of large volume culture to other laboratory methods for isolation of microorganisms from peritoneal dialysate.  Peritoneal Dialysis International 10:49-52.

• C.J. Holmes, S.L. Lewis, R. Evans, W. Kubey, P. Luneburg and D. Mucha (1989). Periodic elevation of complement activation products in peritoneal dialysis effluent of CAPD patients.   ASAIO Transactions XXXV: 587-589.

• C.J. Holmes, R.C. Evans and E. Vonesh (1989).  Comparison of biofilm growth rate of three Staphylococcus epidermidis strains using a negative exponential growth curve model.  Biomaterials 10(9):625-629.

• C.J. Holmes, W.Y. Kubey and D.I. Love (1988).  The survival of microorganisms in 5-fluorouracil and cisplatin solutions stored at room temperature.  American Journal of Hospital Pharmacy 45:1089-1091

• C.J. Holmes, R.C. Evans and B.S. Spinowitz (1988).  Biofilm in CAPD: an update. Advances in Continuous Ambulatory Peritoneal Dialysis; Proceedings of the 8th Annual CAPD meeting, Kansas City, MO. p. 257-263.

• R.C. Evans and C.J. Holmes (1987).  In vitro modeling of a biomaterial associated Staphylococcal biofilm.  Advances in Continuous Ambulatory Peritoneal Dialysis; Proceedings of the 7th Annual CAPD Conference, Kansas City, MO. p. 93-99.

• M. Salit, J. Chase, W. Kubey, C.J. Holmes, F. Pearson, R. Kroes, J. Sensibar and C. Lee (1987).  Partial characterization of peritoneal dialysis effluents by two dimensional gel electrophoresis.  Advances in Continuous Ambulatory Peritoneal Dialysis; Proceedings of the 7th Annual CAPD Conference, Kansas City, MO, p. 13-17.

• R.C. Evans and C.J. Holmes (1987).  Effect of vancomycin hydrochloride on a silicone elastomer associated Staphylococcus epidermidis biofilm.  Antimicrobial Agents and Chemotherapy 31(6):889-894.

• D.I. Love, W.Y. Kubey and C.J. Holmes (1987).  A laboratory method to evaluate formulation effects on the in vitro antimicrobial activity of topical creams and ointments.  Burns 13(3):204-207.

• C.J. Holmes and R.C. Evans (1986).  Invited Review: Biofilm and foreign body infection; the significance to CAPD associated peritonitis.  Peritoneal Dialysis International 6(4):168-177.

• J.J. Chase, W.Y. Kubey, M.H. Dulek, C.J. Holmes, M.G. Salit, F.C. Pearson and E. Ribi (1986).  Effect of Monophosphoryl lipid A on host resistance to bacterial infection.  Infection and Immunity 55:711-712.

• C.J. Holmes (1986).  Evaluating growth of bacteria and fungi in total nutrient admixtures.  American Journal of Hospital Pharmacy 43:1686.

• C.J. Holmes (1985).  Microbial growth comparisons of five commercial parenteral lipid emulsions.  Journal of Parenteral and Enteral Nutrition 9(6):765.

• C.J. Holmes, C. Miyake and W.Y. Kubey (1984).  Evaluation of an ultraviolet germicidal system for CAPD.  Peritoneal Dialysis International 4(4):215-218.

• C.W. Walter, J.A. Pauly, R.K. Ausman, R.B. Kundsin and C.J. Holmes (1983).  Microwave thawing of frozen parenteral solutions.  Medical Instrumentation 17:307-308.

• C.J. Holmes, R.K. Ausman, C.W. Walter and R.B. Kundsin (1982).  The effect of freezing and microwave thawing on the stability of selected antibiotic admixture solutions.  American Journal of Hospital Pharmacy 39:106-108.

• W.Y. Kubey and C.J. Holmes (1982).  A warning on the use of non-sterile cotton gauze on CAPD connections.  Peritoneal Dialysis International 2(4):194.